HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Spero Therapeutics (NASDAQ:SPRO) and maintained a $7 price target.
September 05, 2023 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Spero Therapeutics (NASDAQ:SPRO) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $7.
The 'Buy' rating from HC Wainwright & Co. indicates a positive outlook for Spero Therapeutics. The maintained price target of $7 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100